The pooled results showed that PD-L1 overexpression could predict poor overall survival (HR 1.45, 95% CI 1.11-1.90, <i>P</i> < 0.01), metastasis-free survival (HR 1.58, 95% CI 1.14-2.19, <i>P</i> < 0.01), and event-free survival (HR 2.82, 95% CI 1.69-4.71, <i>P</i> < 0.01) in sarcomas. Here, CD274 is linked to sarcoma.